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The cholesterol-dependent cytolysins (CDCs) constitute a large
family of pore-forming toxins that function exclusively on choles-
terol-containing membranes. A detailed analysis of the various
stages in the cytolytic mechanism of three members of the CDC
family revealed that significant depletion of cholesterol from the
erythrocyte membrane stalls these toxins in the prepore complex.
Therefore, the depletion of membrane cholesterol prevents the
insertion of the transmembrane -barrel and pore formation.
These unprecedented findings provide a paradigm for the involve-
ment of cholesterol in the CDC cytolytic mechanism and that of
other pore-forming toxins whose activity is enhanced by the
presence of membrane cholesterol.
The cholesterol-dependent cytolysins (CDCs) contribute tothe pathogenesis of a large number of Gram-positive bacte-
rial pathogens and belong to a superfamily of structurally
unrelated pore-forming toxins recently termed the -pore-
forming toxins (-PFTs) (1). The CDC cytolytic mechanism
requires the presence of membrane cholesterol, and for over two
decades cholesterol has been considered to be the receptor for
the CDCs (reviewed in refs. 2 and 3) based on several lines of
evidence including one that CDCs are not cytolytically active on
cholesterol-deficient membranes and another that the depletion
of membrane cholesterol reduces the extent of membrane bind-
ing to various eukaryotic cell types (4). Many studies, primarily
performed with perfringolysin O (PFO), have shown that mem-
brane binding is sensitive to the loss of cholesterol (4–11) and
that derivatives of PFO have been used as probes for membrane
cholesterol (12–15).
However, studies on other members of the CDC family suggest
that the loss of membrane binding may not account for the
extreme sensitivity of these toxins to membrane cholesterol
levels. The CDC from Streptococcus intermedius, intermedilysin
(ILY), exhibits an exquisite specificity for human cells (16),
suggesting that cholesterol cannot be responsible for membrane
recognition by ILY, yet its mechanism still seems sensitive to
cholesterol (16). Also, Jacobs et al. (17) have shown that the
addition of exogenous cholesterol inhibited the activity of the
CDC listeriolysin O (LLO) but did not prevent its binding to
the membrane. Hence, the mechanism by which cholesterol
affects the cytolytic activity of the CDCs remains ambiguous
even though the dependence of the CDC cytolytic mechanism on
the presence of membrane cholesterol is the defining property of
these toxins.
These inconsistencies in cholesterol’s role in the CDC mech-
anism prompted us to make a detailed examination of the effects
of cholesterol on each stage of the cytolytic mechanism of three
different CDCs: PFO, streptolysin O (SLO), and ILY. In stark
contrast to the dogma that cholesterol sensitivity of the CDCs
resides in the receptor-binding event, we have found that the
depletion of membrane cholesterol of human erythrocytes pre-
vents insertion of the transmembrane -barrel and traps the
CDCs in the prepore complex.
Materials and Methods
Bacterial Strains, Plasmids, and Chemicals. The gene for PFOC459A
(cysteine-less derivative of PFO) was cloned into pTrcHisA
(Invitrogen) and expressed as described (18). DNA sequencing
was carried out by the DNA sequencing Core Facility at the
Oklahoma Medical Research Foundation (Oklahoma City, OK).
All chemicals and enzymes were obtained from Sigma except
where noted. Cholesterol was obtained from Avanti Polar Lipids.
All f luorescent probes were obtained from Molecular Probes.
Generation and Purification of PFO, SLO, ILY, and Their Derivatives.
Amino acid substitutions in the various genes for PFO, SLO, and
ILY were generated either by PCR overlap mutagenesis (19) or
PCR QuikChange mutagenesis (Stratagene) by using the gene
for a cysteine-less derivative of PFO (18), or SLO (E.M.H. and
R.K.T., unpublished results). The gene for ILY was cloned from
the Gram-positive bacteria S. intermedius by using the following
pTrcHisA vector primers for ILY: BamHI-GGGCCGGATC-
CGAAACACCTACCAAACCAAAAGC and EcoRI-GGGC-
CCTTAAGTTAATCAGTGTTATCTTTCACAAC. The gene
for SLO was cloned from Streptococcus pyogenes by using the
following pTrcHisA vector primers for SLO: BamHI-
CCGCGGATCCGCTCCCAAAGAAATGCCACTA and
EcoRI-CGACGAATTCCTACTTATAAGTAATCGAAC-
CATA. Expression and purification of all three proteins and
their derivatives used in this study were carried out as before for
PFO (18).
Hemolytic Activity. The hemolytic activity of each toxin on native
and cholesterol-depleted human erythrocytes (hRBCs) was de-
termined as previously described by Shepard et al. (18). The
HD50 is defined as the concentration of toxin required to lyse
50% of the hRBCs in 50 l of PBS containing 2.5  106
hRBCs.
Membrane Cholesterol Depletion and Restoration. Cholesterol ex-
traction with methyl--cyclodextrin was done as described (20)
with modifications. Freshly drawn hRBCs were pelleted by
centrifugation at 1,500 g for 8 min and washed three times with
PBS [10 mM Na2HPO4 (pH 7.5) containing 147 mM NaCl and
3 mM KCl]. Cholesterol depletion was accomplished by sus-
pending the hRBCs in PBS containing 3.5 mM methyl--
cyclodextrin (MCD) [final hematocrit of 5% (volvol)] for 120
min at 37°C. The hRBCs were washed three times with PBS to
remove the MCD and associated cholesterol. Half of the cells
were used for flow cytometry, and the other half were used to
determine cholesterol content (Cholesterol 20 assay, Sigma).
The relative depletion of the MCD was equal to the concen-
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tration of cholesterol in the native hRBCsconcentration of
cholesterol in the native hRBCs. Approximately 90% of the total
hRBC cholesterol was removed primarily because erythrocyte
cholesterol is almost entirely associated with the plasma mem-
brane of erythrocytes (20).
To restore cholesterol to the cholesterol-depleted hRBCs, the
cells were centrifuged and suspended in a buffer containing
cholesterolMCD prepared as described (21) except that cho-
lesterol was added to make a final concentration of 4 mM in 10
ml of buffer A (140 mM NaCl5 mM KCl5 mM KH2PO41 mM
MgSO410 mM Hepes5 mM glucose, pH 6.5) containing 5 mM
MCD. Depleted cells were suspended in the cholesterol-loaded
MCD buffer A to a final hematocrit of 5% (volvol) and
incubated for 120 min at 37°C. The cells were then washed
three times in PBS to remove any residual cholesterol–MCD
complex.
Modification of Proteins with Fluorescent Probes. The labeling of the
PFO, ILY, and SLO derivatives was carried out as described for
PFO (22) except that Alexa Fluor 488 C5 maleimide or iodoacet-
amido-N,N-dimethyl-N-(iodoacetyl)-N-(7-nitrobenz-2-oxa-
1,3-diazolyl)ethylene-diamine (NBD; Molecular Probes) was
used to label the proteins. The dye-labeled protein samples were
made 10% (volvol) in glycerol, quick-frozen in liquid nitrogen,
and stored at 80°C.
Membrane Binding by Flow Cytometry. Binding of each toxin
labeled with Alexa Fluor 488 to hRBCs was determined as
follows. To minimize any effects from self-quenching of the
fluorescent probes, equimolar amounts of dye-labeled and un-
labeled toxin were used in each experiment to sufficiently
separate the dye molecules in the oligomer (23). Approximately
4.5 pmol each of dye-labeled toxin and unlabeled toxin were
equilibrated at 4°C with 50 l of PBS containing 0.1% BSA.
Freshly drawn (washed three times in buffer A) hRBCs (1.5 
106; 25–30 l) were added to the toxin mixture at 4°C and
allowed to incubate for 30 min. The hRBCs with bound toxin
were then diluted to a final volume of 400 l in PBS at 4°C and
analyzed by using a FACSCalibur flow cytometer (University of
Oklahoma Health Sciences Center) and FLOWJO software (Tree
Star, San Carlos, CA). The emission wavelength was set to 530
nm, and the excitation was set at 488 nm with a bandpass of
30 nm.
Fluorescence Resonance Energy Transfer (FRET) by Flow Cytometry.
FRET-based flow cytometry experiments were similar to those
performed for binding experiments, with the following changes.
Equimolar amounts (4.5 pmol each) of donor-labeled toxin (D)
(Alexa Fluor 488-labeled toxin) and either unlabeled toxin (U)
or acceptor-labeled toxin (A) (tetramethylrhodamine-labeled
toxin) were added to native or cholesterol-depleted hRBCs. The
mixtures were then analyzed by flow cytometry as in the binding
experiments. Changes in the donor fluorescence due to FRET
were determined by comparing donor fluorescence in the pres-
ence of acceptor-labeled toxin (D  A) to that when acceptor
was replaced with unlabeled toxin (D  U). The net change in
intensity due to FRET was determine by comparison of D  U
and D  A. The emission and excitation settings were as
described above for the binding analysis.
Membrane Insertion Measurements by Flow Cytometry. The change
in fluorescence intensity of the NBD fluorophore attached to
PFOA215C when buried in the bilayer during insertion of trans-
membrane -hairpin 1 (TMH1) has been described (24). For
SLO and ILY, we placed the NBD-probe at the analogous
residues, SLOS287C and ILYH242C. Samples containing 9 pmol of
NBD-labeled PFO, SLO, or ILY were incubated with 1.5  106
hRBCs at 4°C for 30 min to allow toxin to bind and oligomerize.
These samples were then analyzed by flow cytometry. To
stimulate the insertion of the transmembrane -hairpins, the
sample was shifted to 37°C for 10 min (24) and was analyzed
again by flow cytometry. The emission and excitation wave-
lengths and the bandpass setting for the flow cytometer were the
same as for the binding analysis.
To confirm that NBD probe was inserted into the membrane,
the toxin-treated native and cholesterol-depleted erythrocyte
samples from the above experiments were equilibrated with 50
g of a 1:1 mixture of 5- and 16-doxyl-stearic acid (Sigma) in
MeOH by gentle vortexing at room temperature. The samples
were then analyzed by flow cytometry as described above.
SDSAgarose Gel Electrophoresis (SDSAGE) and Immunoblot Analy-
ses. Denaturing agarose gel electrophoresis was carried out as
established by Shepard et al. (18) except that each toxin (9 pmol)
was incubated with 1.5  106 native or cholesterol-depleted
hRBCs for 30 min at 37°C.
hRBC Ghost Membrane Preparation. hRBC ghost membranes were
prepared as described (23) with some modifications. After
hypotonic lysis of the hRBCs, cytoplasmic constituents were
separated from the membranes by dialysis with 2 liters of the lysis
buffer [5 mM sodium phosphate (monobasic), pH 7.5, contain-
ing 1 mM EDTA] by recirculation through a Filtron tangential
f low Centramate unit (Pall) equipped with 100-kDa cutoff
membranes at 20 psi (1 psi  6.89 kPa). Membrane protein
concentration was determined by the method of Bradford (25)
by using BSA as the protein standard.
Steady-State Fluorescence Spectroscopy. Fluorescence intensity
measurements were performed by using an SLM-8100 photon-
counting spectrofluorimeter equipped with a dual grating exci-
tation monochromator, a single emission monochromator with a
Peltier-cooled photomultiplier tube, and a 450-watt xenon lamp
as described (18). An excitation wavelength of 470 nm was used
for NBD, and the emission intensity was measured from 500 to
600 nm; the bandpass was 2 nm for all NBD measurements.
Emission scans of each sample were carried out at a resolution
of 1 nm with an integration time of 1 s. In a typical experiment,
17 pmol of toxin was incubated alone or in the presence of native,
cholesterol-depleted, or cholesterol-replete erythrocyte ghost
membranes (equivalent to 10 g of membrane protein) for 30
min at 37°C. Data obtained from control samples with or without
membranes containing unlabeled toxin were subtracted from the
fluorescence spectra to determine the net fluorescence intensity.
Fluorescence quenching experiments were performed in the
same manner except the membranes were equilibrated with a 1:1
(wtwt) mixture of 5- and 16-doxyl-stearic acid quenchers to
introduce a nitroxide into the bilayer core. Each probe was
dissolved in MeOH to a final concentration of 50 mgml.
Erythrocyte ghost membranes were equilibrated with 200 g of
probe per 1 mg of membrane protein. The doxyl-stearic acid was
equilibrated with the membranes for 10 min at room tempera-
ture with gentle rocking. Unincorporated probe was removed by
washing the membranes three times in buffer A.
Results
Depletion of Membrane Cholesterol Abolishes CDC-Dependent Eryth-
rocyte Lysis. The effect of cholesterol depletion on the sensitivity
of hRBCs to lysis by PFO, SLO, or ILY was initially examined
to confirm that the cytolytic mechanism of all three toxins was
indeed sensitive to the loss of membrane cholesterol. The
hemolytic dose for 50% lysis (HD50, see Materials and Methods)
was determined for each toxin by using native hRBCs and
hRBCs depleted of90% of their membrane cholesterol (Table
1) with the cholesterol-sequestering agent MCD (20, 26).
The loss of membrane cholesterol resulted in a 11,000-fold
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increase in the HD50 of PFO, a4,400-fold increase in the HD50
for SLO, and a3,000-fold increase in the HD50 for ILY (Table
1). In all cases, the hemolytic activity of each toxin was reduced
to 0.1% of its original activity, confirming that all three CDCs
were highly sensitive to the loss of membrane cholesterol.
Furthermore, the HD50 for all toxins was fully recovered when
cholesterol was restored to the erythrocyte membrane by incu-
bating the same depleted hRBCs with cholesterol-saturated
MCD inclusion complexes (Table 1) before carrying out the
hemolytic assay. The latter experiment confirmed that only the
loss of cholesterol was responsible for the loss of activity and not
another component of the membrane that may have been
coincidentally extracted by the MCD treatment.
Cellular Binding of PFO, SLO, and ILY to Cholesterol-Depleted hRBCs.
Membrane binding of PFO, SLO, and ILY to native and
cholesterol-depleted hRBCs (as prepared above) was deter-
mined by using fluorescent-labeled toxins and flow cytometry.
All toxins were extrinsically labeled at approximately a 1:1 molar
ratio with the fluorescent dye at a unique cysteine in each toxin
(see Materials and Methods). Because the toxin was directly
labeled at an equimolar ratio with the fluorescent dye, any
fluorescence-detected changes in binding determined by flow
cytometry will accurately reflect the number of bound toxin
molecules. Using extrinsically labeled toxin minimizes the in-
herent inaccuracies associated with indirect assays by using, for
example, f luorescently tagged antibody to detect the toxin,
where the number of dyes per antibody can vary and where the
ratio of antibody to toxin could vary depending on the structural
state of the toxin.
As can be seen in Fig. 1, cholesterol extraction decreased PFO
binding by 10-fold. Surprisingly, SLO and ILY binding to the
hRBCs was largely unaffected by the depletion of membrane
cholesterol (Fig. 1), whereas their hemolytic activity on the same
hRBCs was reduced 99.9% (Table 1). Furthermore, the
11,000-fold decrease in hemolytic activity of PFO did not
correlate with the 10-fold decrease in binding. These observa-
tions suggested that another stage of the mechanism was sensi-
tive to the loss of cholesterol.
Oligomer Formation by the CDCs on Native and Cholesterol-Depleted
Erythrocytes. After membrane binding, the CDC monomers
diffuse laterally on the membrane and interact with one another
to form a large oligomerized prepore complex (22, 24). When the
prepore is formed, the complex inserts its transmembrane
-sheet (22, 24, 27, 28). The capacity of bound PFO, SLO, and
ILY to oligomerize into a prepore complex was examined on
native and cholesterol-depleted hRBCs by FRET by using flow
cytometry, and these results were confirmed by the direct
examination of oligomer formation by SDSAGE.
FRET between donor- and acceptor-labeled toxin molecules
was determined by flow cytometry to examine the oligomeriza-
tion of each toxin under conditions similar to the binding
experiments. Equimolar amounts of donor-labeled toxin (Alexa
Fluor-labeled toxin) and either unlabeled toxin (D  U) or
acceptor-labeled toxin (DA) were used. As can be seen in Fig.
2, the magnitude of donor intensity decreased when the unla-
beled toxin was replaced with acceptor-labeled toxin. Further-
more, the magnitude of the change was similar on both native
and cholesterol-depleted hRBCs for all three toxins. As ex-
pected, the peaks of fluorescence intensity of the PFO in the
absence and presence of the acceptor-labeled PFO were both
shifted to the left (decreased total f luorescence) on the choles-
terol-depleted membranes because PFO binds less efficiently to
cholesterol-depleted membranes (Fig. 1). The magnitude of the
change in the fluorescence intensity of the donor due to FRET
in the presence of acceptor-labeled PFO was similar on both the
native and cholesterol-depleted membranes, suggesting that,
although less PFO was bound, the bound PFO oligomerized to
the same extent as that on the native hRBCs.
We confirmed these observations by examining the formation
of oligomers on the hRBCs by SDSAGE (22, 24, 27). Again,
Table 1. Hemolytic activity on native, cholesterol-depleted, and
cholesterol-replete hRBCs
CDC
HD50, fmol
Fold change
nativeChol
Native
hRBCs
Cholesterol-
depleted hRBCs
Cholesterol-
replete hRBCs
PFO 9.8 86,000 9.2 11,000
SLO 20.0 89,000 26.5 4,400
ILY 5.6 17,000 6.6 3,000
The HD50 (hemolytic dose for 50% lysis; see Materials and Methods) of PFO,
SLO, and ILY was compared among native hRBCs, hRBCs depleted of 90% of
the membrane cholesterol, and cholesterol-depleted hRBCs to which choles-
terol was restored by using cholesterol-loaded MCD.
Fig. 1. Binding to native hRBCs and cholesterol-depleted hRBCs. Binding of
fluorescently labeled derivatives of PFOA215C, SLOG128C, and ILYS57C to hRBCs
was determined by flow cytometry. The fluorescent-labeled toxin (4.5 pmol)
was mixed with an equimolar amount of unmodified toxin, incubated with
1.5  106 hRBCs at 4°C for 30 min, and then analyzed by flow cytometry. We
counted 104 cells per sample. Toxin binding to native (outlined peak) and
cholesterol-depleted (shaded peak) hRBCs is shown for all three toxins.
Fig. 2. Oligomerization measured by FRET and flow cytometry. Equimolar
amounts (4.5 pmol each) of donor-labeled toxin (Alexa Fluor-labeled toxin)
and either unlabeled (D  U, solid line) or acceptor-labeled (D  A, dashed
line) toxin (tetramethylrhodamine-labeled toxin) were incubated with 1.5 
106 hRBCs at 4°C for 30 min and then analyzed by flow cytometry. 104 cells per
sample were counted. The fluorescence intensity of the donor fluorophore is
shown for all three toxins on native and cholesterol-depleted hRBCs in the
presence of unlabeled (D  U) or acceptor-labeled toxin (D  A). FRET
between donor- and acceptor-labeled toxin is observed as a decrease in the
fluorescence of the donor when the unlabeled toxin is replaced with acceptor-
labeled toxin (compare D  U and D  A).
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hRBCs were treated with each toxin under conditions similar to
those used in the cellular binding assays and the FRET exper-
iments above. The resultant toxin oligomers were then resolved
from monomer by SDSAGE (24). The prepore and pore
oligomers of the CDCs are resistant to dissociation by SDS at
37°C although the prepore complex is slightly less resistant to
dissociation than the pore complex (22). After separation of the
proteins by SDSAGE, the proteins were transferred to nitro-
cellulose paper, and the monomer and oligomer bands were
identified by using toxin-specific antibodies. In all cases, signif-
icant oligomer is present on both native and cholesterol-depleted
hRBCs (Fig. 3). However, because 10-fold less PFO binds to
the cholesterol-depleted hRBCs, we see an overall reduction of
the oligomer band. For both SLO and ILY, slightly less oligomer
is present on the cholesterol-depleted membranes. However, the
slight difference in the intensity of the oligomer bands cannot
account for the loss of 99.9 of the hemolytic activity. Hence,
cholesterol levels did not significantly affect the oligomerization
of the toxins after they were bound to the membrane.
Membrane Insertion of the CDC Transmembrane -Barrel Requires the
Presence of Membrane Cholesterol. The final step in the CDC
cytolytic mechanism is the conversion of the prepore complex to
the pore complex by the insertion of the TMHs (18, 22, 24, 27,
29, 30). The insertion of the TMHs of all three toxins was
detected by the increase in the fluorescence intensity of the
fluorescent NBD probe when attached to a cysteine that has
been substituted for a membrane-facing residue within TMH1 of
PFO, SLO, or ILY (18, 22, 27, 29, 30). The location of the probe
within the membrane is confirmed by collisional quenching by a
nitroxide-labeled lipid (doxyl-stearic acid) that is introduced into
the bilayer (18, 29).
The insertion of the transmembrane domains for each toxin
was first examined on native and cholesterol-depleted hRBCs by
flow cytometry under conditions identical to those used in the
binding and FRET assays. However, in this case, we used the
NBD-labeled derivatives of PFO, SLO, and ILY instead of
the Alexa Fluor dye to detect insertion by an increase in
fluorescence intensity as NBD moves into the hydrophobic
environment of the bilayer. Initially, the fluorescence intensity
of the NBD was determined after the toxins had formed the
prepore complex on hRBCs by maintaining the temperature at
4°C (24, 28). As can be seen in all cases, the fluorescence
intensity of the peaks was much lower than that observed for
Alexa Fluor-labeled toxin because of the low quantum yield of
NBD in a polar environment (Fig. 4). The sample was then
warmed to 37°C to trigger the insertion of the transmembrane
domains of the prepore to form the pore complex. For all toxins
there is a significant increase in the fluorescence intensity of
each sample indicating that the NBD had moved into a nonpolar
environment (Fig. 4), presumably the membrane bilayer.
The location of the NBD in the bilayer was confirmed by
incubating the same sample with 5- and 16-doxyl-stearic acid.
The stearic acid quickly partitions into the membrane, thereby
placing the nitroxide within the bilayer core (31). If the insertion
of the toxin transmembrane domain places the NBD probe
within the membrane, then the increase in the NBD fluorescence
intensity observed as a result of insertion of the TMH into the
bilayer should be significantly quenched by the presence of the
membrane-restricted nitroxide. In all cases the fluorescence
intensity of each inserted toxin is quenched to or below the
fluorescence intensity of the uninserted prepore at 4°C, showing
that each probe had inserted into the membrane (Fig. 4).
In contrast, there is little or no insertion of the toxins on the
cholesterol-depleted hRBCs because little or no change in the
fluorescence intensity of the NBD was observed when these
samples were shifted to 37°C (Fig. 4). Therefore, it seems that the
insertion of the TMHs into the membranes of the cholesterol-
depleted cells did not occur. As expected, no decrease in the
already low fluorescence intensity observed in these samples
occurred when the hRBCs were equilibrated with the doxyl-
stearic acid because there is no insertion of the TMHs. These
observations strongly correlate with the loss of cytolytic activity
on depletion of membrane cholesterol and suggest that the
Fig. 3. Oligomer formation on native and cholesterol-depleted hRBCs de-
termined by SDSAGE. The formation of oligomers of PFO, SLO, and ILY was
determined by SDS-agarose electrophoresis. Each toxin (9 pmol) was incu-
bated alone (SM, soluble monomer), or with 1.5 106 native (NM) or choles-
terol-depleted (CDM) hRBCs for 30 min at 37°C. The samples were solubilized
with SDS sample buffer, the monomer and oligomeric complexes were re-
solved on a 1.5% SDSAGE gel and immunoblotted, and the toxin was de-
tected with specific antibody. Shown are the autoradiograms of the monomer
and oligomer bands recognized by the antibody. Immunoblot analysis of
untreated erythrocytes did not reveal any cross-reactive proteins (data not
shown).
Fig. 4. Membrane insertion into native and cholesterol-depleted hRBCs.
PFO, SLO, or ILY (9 pmol each), each labeled with NBD in a membrane-facing
residue in TMH1, were incubated with 1.5  106 hRBCs at 4°C for 30 min and
analyzed by flow cytometry. At 4°C, binding and oligomerization proceed, but
insertion of the TMHs is significantly inhibited (24). Each sample was then
shifted to 37°C for an additional 10 min to allow insertion of the TMHs and
then was analyzed again by flow cytometry for changes in NBD emission. To
confirm that the increase in NBD intensity seen with native hRBCs was due to
TMH membrane insertion, the same sample was equilibrated with the colli-
sional quencher doxyl-stearic acid (37°CNO), which places a nitroxide in the
bilayer of the erythrocytes. The sample was then analyzed for a third time by
flow cytometry. We counted 104 cells per sample in all experiments. Changes
in the NBD intensity are shown for the toxins incubated with native (outlined
peak) and cholesterol-depleted (shaded peak) hRBCs under each condition.
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inability of these toxins to insert their TMHs is responsible for
loss of the cytolytic activity.
Because flow cytometry has not been previously used to
measure membrane insertion of a transmembrane domain, we
confirmed these results by using spectrofluorimetric methods to
measure insertion of the TMHs into the bilayer of purified
membranes from hRBCs (18). As can be seen in Fig. 5, the
fluorescence intensity of the NBD probe in all three toxins
increases significantly when the toxins are incubated with puri-
fied native erythrocyte ghost membranes (compare the fluores-
cence intensity of the soluble monomer to membrane-inserted
oligomer on native membranes). Although the net increase for
these toxins differed, the difference likely results primarily from
differences in the starting environment of the probe in the
soluble monomer (18, 29). NBD probes that occupy a more
nonpolar site within the monomeric soluble protein will exhibit
a smaller net increase in fluorescence intensity because they are
moving from one nonpolar environment to another (i.e., the
membrane core).
In agreement with the experiments shown in Fig. 4, the
insertion of the TMHs did not occur on membranes derived from
cholesterol-depleted hRBCs because the fluorescence intensity
of the NBD probe remained the same as that of the soluble
monomer in the absence of membranes (Fig. 5). On restoration
of cholesterol to the cholesterol-depleted membranes, the in-
tensity of the NBD increased to that observed when the toxins
were incubated with native membranes, showing that only
cholesterol was responsible for the loss of TMH insertion in the
cholesterol-depleted membranes. We also examined the effect of
adding cholesterol back to the membrane after the oligomeric
complex of PFO had been preformed on cholesterol-depleted
membranes. We found that the prepore could also efficiently
insert under these conditions, indicating that the prepore oli-
gomer that was formed on cholesterol-depleted membranes was
still capable of insertion (data not shown).
The membrane location of the NBD-labeled residues was
again confirmed for all three toxins by the accessibility of the
NBD probe to collisional quenching by the membrane restricted
5- and 16-doxyl-stearic acid (Fig. 5). Although residue 215 of
TMH1 of PFO has been rigorously demonstrated to enter the
membrane (18) and has been used extensively to measure
insertion of the PFO -barrel (22, 24, 27, 29, 30), the equivalent
residues of SLO and ILY have not. The NBD located at the
equivalent positions in SLO and ILY also exhibits an increase in
fluorescence intensity when incubated with membranes isolated
from native hRBCs. Furthermore, the NBD located at these
positions is collisionally quenched by the introduction of the 5-
and 16-doxyl-stearic acid into those membranes (Fig. 5). There-
fore, each of these residues faces the membrane bilayer and is a
reliable indicator of TMH1 insertion by SLO and ILY.
Discussion
These studies show that the loss of prepore to pore conversion
is the basis for the extreme sensitivity of CDC pore formation to
the concentration of membrane cholesterol. Each primary in-
dependent step of the mechanism of CDC pore formation has
been examined for its sensitivity to the depletion of membrane
cholesterol from natural membranes. Furthermore, each stage of
the cytolytic mechanism has been examined with three different
CDC members to assess the generality of the cholesterol effect.
In contrast to the long-held dogma that the primary effect of
cholesterol depletion resides in the membrane-binding event, we
have determined that the prepore to pore transition for each of
these toxins is most sensitive to cholesterol depletion. Thus, the
loss of cholesterol from the membrane abrogates cytolytic
activity by preventing the membrane insertion of the transmem-
brane -barrel of the prepore complex.
The results of the initial studies to examine the binding and
cytolytic activity of PFO, SLO, and ILY on native and choles-
terol-depleted hRBCs were unexpected. It was apparent that
SLO and ILY erythrocyte binding was unaffected by the loss of
90% of the membrane cholesterol from the hRBCs, yet their
cytolytic activity on the same cholesterol-depleted hRBCs was
reduced99.9%. Furthermore, even though the binding of PFO
was reduced10-fold on cholesterol depletion of the hRBCs, its
activity was reduced11,000-fold. Therefore, it was evident that
the complete loss of cytolytic activity on the cholesterol-depleted
hRBCs could not be reconciled by changes in the extent of
membrane binding. Hence, the step in the cytolytic mechanism
of the CDCs that was responsible for the hallmark sensitivity of
these toxins to membrane cholesterol had to lie elsewhere in the
mechanism.
When the oligomerization states of the bound CDCs were
examined on native and cholesterol-depleted hRBCs, it was
apparent that the depletion of membrane cholesterol did not
significantly impact the conversion of bound monomer to oli-
gomer although there seemed to be slightly less oligomer on the
membrane of cholesterol-depleted hRBCs. Except in the case of
PFO, this difference is probably due to the fact that the prepore
oligomer of PFO is somewhat more sensitive to dissociation by
SDS than is the pore complex (22, 27). The prepore is an
oligomerized complex of the CDC monomers that has not yet
inserted its transmembrane -barrel and formed a pore. We have
previously shown that the prepore complex is an essential
intermediate in the pore-forming mechanism of these toxins (22,
24, 27, 28). PFO can be stalled or trapped in a prepore state by
low temperature (24) or by various mutations within the PFO
structure (22, 27). Likewise, cholesterol-depleted membranes
trapped all three CDCs in the prepore state and prevented the
insertion of the transmembrane -barrel into the membrane and,
therefore, pore formation. All three toxins regained full activity
Fig. 5. Membrane insertion into native hRBC, cholesterol-depleted, or
cholesterol-replete membranes. The fluorescence intensity of the same NBD-
labeled toxin used for the experiments in Fig. 4 was determined when they
were incubated alone (SM, soluble monomer) or with erythrocyte ghost native
membranes (NM), cholesterol-depleted membranes (CDM), or cholesterol-
replete membranes (CRP). The samples were incubated for 30 min at 37°C, and
the emission intensities of the NBD for each sample were measured between
500 and 600 nm. To confirm that the NBD-labeled residues of SLO and ILY were
membrane facing, the same experiment was repeated for each labeled toxin
in the absence and presence of the membrane collisional quencher doxyl-
stearic acid (graph labeled NO). Only the net emission intensity of the NBD at
540 nm [(FmembFsoluble)  1] is shown for the membrane-inserted toxin on
native membranes (NM) vs. membranes containing the doxyl-stearic acid
collisional quencher (NM  NO).
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if cholesterol was restored to the membrane, and so it is the loss
of cholesterol alone that affects the prepore to pore conversion.
These studies therefore show that the loss of cholesterol from the
membrane traps PFO, as well as SLO and ILY, in their prepore
complex and is primarily responsible for the hallmark sensitivity
of the CDCs to membrane cholesterol.
Does cholesterol still function as the membrane receptor for
these toxins? It is clear that PFO binding is reduced by depletion
of membrane cholesterol although the extent of the reduction in
binding was substantially less than the decrease in cytolytic
activity. Thus, our data do not rule out an important role for
cholesterol in the binding of some CDCs to the membrane, but
it is clear that pore formation by PFO, SLO, and ILY is far more
sensitive to cholesterol depletion of natural membranes than is
their binding. This result was particularly evident for SLO and
ILY because neither exhibited any significant change in binding
on the cholesterol depleted membranes, yet both toxins were
inactive on cholesterol-depleted cells. Therefore, although cho-
lesterol may still function as a receptor for some or all CDCs at
low concentrations, it is the loss of prepore to pore conversion
that is most sensitive to membrane cholesterol levels.
The results of the present studies may also provide a paradigm
for the general effect of cholesterol on the mechanism of widely
divergent pore-forming toxins. Linder and Bernheimer (32)
observed nearly two decades ago that the cytolytic activity of
several pore-forming toxins was decreased by the depletion of
membrane cholesterol. Since that time, the presence of mem-
brane cholesterol has been found to enhance pore formation for
the sea anenome-derived pore-forming toxin sticholysin II (33),
Staphylococcus aureus alpha hemolysin (34), aerolysin (35), the
earthworm-derived hemolysin eiseniapore (36), the Escherichia
coli hemolysin ClyA (SheA) (37), and the Vibrio cholerae he-
molysin (38). One explanation for the common enhancement of
pore-formation is that cholesterol may interact with these toxins
in such a way as to promote insertion of their transmembrane
domains andor by the promotion of certain membrane struc-
tures (inverted hexagonal phases) (39) that may facilitate the
insertion of the transmembrane domains. Therefore, the en-
hancement in the conversion of pore-forming toxins to the
membrane-inserted state may be a common effect of membrane
cholesterol.
The studies herein show that the dominant effect of choles-
terol on the CDC mechanism is to promote the insertion of the
transmembrane -barrel. These studies also provide a paradigm
for the basis of cholesterol dependence for other pore-forming
toxins whose mechanism is enhanced by the presence of mem-
brane cholesterol.
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